Cyproterone acetate (CPA), a highly potent steroidal anti-androgen was one of the first drugs approved for the treatment of PCa that acts by competing with endogenous AR ligands, DHT, and testosterone for binding to the AR (124). Here, AR is linked to posterior cortical atrophy.